David Elsley is the President, CEO, and founder of Cardiol Therapeutics, a clinical-stage biotechnology company focused on developing anti-inflammatory.
David Elsley is the President, CEO, and founder of Cardiol Therapeutics, a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for cardiovascular diseases. He has an MBA and is responsible for leading the company's Phase 3 trial efforts and FDA application strategy for its lead drug candidate, CardiolRx™.
Full founder directory · Investor directory · Company funding database · Fundraising library